Viewing Study NCT00481260



Ignite Creation Date: 2024-05-05 @ 5:33 PM
Last Modification Date: 2024-10-26 @ 9:33 AM
Study NCT ID: NCT00481260
Status: COMPLETED
Last Update Posted: 2009-09-04
First Post: 2007-05-31

Brief Title: Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous
Sponsor: HaEmek Medical Center Israel
Organization: HaEmek Medical Center Israel

Study Overview

Official Title: Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous
Status: COMPLETED
Status Verified Date: 2009-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Hgb C is an hemoglobinopathy quite rare in Israel The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives was not study The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent
Detailed Description: Hgb C is an hemoglobinopathy quite rare in Israel The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives was not study The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent

The study will record the clinical characteristics of the homozygous Hgb C patients and the hematology characteristics of all the heterozygous carriers detected in northern Israel

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None